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Abstract
Background: Peroxisome proliferators-activated receptor alpha (PPARα) activation modulates
cholesterol metabolism and suppresses bile acid synthesis. This study aims to evaluate the effect of
short-term administration of fenofibrate, a PPARα agonist, on proinflammatory cytokines,
apoptosis, and hepatocellular damage in cholestasis.
Methods: Forty male Wistar rats were randomly divided into four groups: I = sham operated, II
= bile duct ligation (BDL), III = BDL + vehicle (gum Arabic), IV = BDL + fenofibrate (100 mg/kg/
day). All rats were sacrificed on 7th day after obtaining blood samples and liver tissue. Total bilirubin,
aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP), gamma-
glutamyl transferase, (GGT), tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1 β), and
total bile acid (TBA) in serum, and liver damage scores; portal inflammation, necrosis, bile duct
number, in liver tissue were evaluated. Apoptosis in liver was also assessed by
immunohistochemical staining.
Results: Fenofibrate administration significantly reduced serum total bilirubin, AST, ALT, ALP, and
GGT, TNF-α, IL-1 β levels, and TBA (P < 0.01). Hepatic portal inflammation, hepatic necrosis,
number of the bile ducts and apoptosis in rats with BDL were more prominent than the sham-
operated animals (P < 0.01). PPARα induction improved all histopathologic parameters (P < 0.01),
except for the number of the bile duct, which was markedly increased by fenofibrate therapy (P <
0.01).
Conclusion: Short-term administration of fenofibrate to the BDL rats exerts beneficial effects on
hepatocellular damage and apoptosis.
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Background
Cholestatic liver diseases are characterized by impaired
hepatocellular secretion of bile, resulting in intracellular
accumulation of bilirubin, bile acids and cholesterol. Bile
duct ligation (BDL) causes complete blockage of choles-
terol excretion, and it is well known that hyperlipidemia
develops in obstructive jaundice. Bile acids are the major
products of cholesterol metabolism in the liver, and act as
physiological detergents that facilitate absorption, trans-
port, disruption of lipid-soluble fats and vitamins; fur-
thermore it also aids in the excretion of lipids. Retention
and accumulation of toxic, hydrophilic bile salts stimu-
lates the production of proinflammatory cytokines and
enhances apoptosis which leads to hepatocellular damage
[1,2]. Apoptosis is an integral part of many biological
processes, including embryonic development, metamor-
phosis, hormone-dependent atrophy, and in chemical-
induced cell death [3,4].
Fibrates are frequently used in the treatment of hyperlipi-
demia and are generally effective in lowering elevated
plasma triglyceride and cholesterol levels [5]. They exert
multiple effects on lipid metabolism pathways by activat-
ing peroxisome proliferator-activated receptor alpha
(PPARα), a specific ligand inducible transcription factor
which controls gene expression through peroxisome pro-
liferators response elements (PPREs) [6]. PPARα agonists
modulate cholesterol metabolism pathways in the liver
[7]. Indeed, fibrates suppress bile acid synthesis, the major
pathway of cholesterol elimination from the body [8,9].
Induction of PPARα increases the size and the number of
hepatocytes within the first few days of exposure. During
this time, spontaneous hepatocyte apoptosis is sup-
pressed within the intact liver [10]. Rodent primary hepa-
tocytes successfully recapitulate the early response to PP
exposure observed in vivo. This shows suppression of
spontaneous apoptosis after PP exposure, as well as apop-
tosis induced TGF beta and fas is PPARα dependent
[11,12]. Therefore, long-term induction of PPARα results
in hepatomegaly and increases hepatocellular hyperplasia
and consequently carcinogenesis in liver [10,12]. PPARα
activation leads to the enhanced apoptosis in normal liver
[13,14]. But its effects on apoptosis in cholestatic liver are
unknown.
Though the reduction of bile salts by induction of PPARα
has been evaluated in variety of studies, there is no evi-
dence about the effects of short-term PPARα induction in
cholestatic liver. It can be assumed that bile salt retention
and altered cholesterol metabolism play central roles in
obstructive jaundice. Therefore, PPARα induction may
attenuate hepatocellular damage. The aim of the present
study is to investigate the effects of short term fenofibrate
treatment, a PPARα receptor agonist, on hepatocellular
damage, oxidative stress, apoptosis and the levels of
proinflammatory cytokines.
Methods
Ethics and Animals
The study was performed on forty male Wistar Albino rats
weighing 230–270 g, and conducted following the exper-
imental protocol approved by Committee for Research
and Animal Ethics of Gazi University. Animals were
housed in stainless steel cages under controlled tempera-
ture and humidity, and with 12-hour dark/light cycles. All
rats were allowed at the least one week of adaptation to
the laboratory before the experimental procedure began.
They were allowed free access to a commercial standard
chow and water ad libitum. Rats were randomly assigned
to four experimental groups each containing ten rats as
follows:
Group 1 (Sham, n = 10): underwent a sham operation.
Group 2 (BDL, n = 10): had common bile duct ligation
(BDL)
Group 3 (BDL + vehicle, n = 10): had BDL and adminis-
tered gum arabic by gavage.
Group 4 (CBDL + fenofibrate, n = 10): had BDL and
given fenofibrate by gavage.
Sham-operated rats served as a control group.
Operative Procedures
Each rat was weighed and anesthetized by intraperitoneal
administration of 40 mg/kg ketamine (Ketalar®, Parke
Davis, Eczacýbasi, Istanbul, Turkey) and 5 mg/kg xylo-
caine (Rompum®, Bayer AG, Leverkusen, Germany). The
abdomen was shaved and disinfected with 10% povidone
iodine. Following a midline incision, the common bile
duct was exposed and a double-ligature with 5-0 silk was
performed and the bile duct was sectioned between the
ligatures. In the sham-operated animals the common bile
duct ligation (BDL) was freed from surrounding soft tis-
sue without ligation and transaction. Abdominal incision
was closed in layers with 4-0 dexon and 2-0 nylon. Ani-
mals received standard rat chow during experiment.
Preparation and Administration of Fenofibrate
Fenofibrate (Lipofen, Nobel Drug Industry, Istanbul) was
dissolved 3% aqueous sterile solution of gum Arabic.
Fenofibrate solution was administered as a single dose of
100 mg/kg via gavage for the first to sixth postoperative
days [15]. The oral dose and duration of the gum arabic of
group 3 was the same used in treated groups.BMC Gastroenterology 2007, 7:44 http://www.biomedcentral.com/1471-230X/7/44
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Harvest of Tissue and Blood Samples
Seven days after the surgical procedures the animals were
anesthetized, and relaparotomy was performed. After
blood samples were drawn, the liver was carefully dis-
sected out from its attachment, and totally excised. All rats
were then sacrificed by hemorrhage. The blood samples
were kept at -80°C for biochemical analyses which were
duplicates. Liver tissue was fixed in 10% neutral phos-
phate-buffered formalin, and then embedded in paraffin
wax.
Blood Biochemistry
The serum bilirubin level was determined with a Cobas
Bio (Hoffman La Roche, Basel, Switzerland) using direct
bilirubin test (Hoffman La Roche, Basel, Switzerland).
The serum activity of aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase (ALP)
gamma-glutamyl transferase, (GGT were measured by
using commercially available kits (Boehringer, Man-
nheim, Germany). Total bile acid (TBA) was determined
using an analytical kit from Sigma, USA with a 747 auto-
matic biochemistry analyzer.
Serum Tumor Necrosis Factor-α and Interleukin-1β Assay
In order to determine the levels of TNF-α and IL-1β, a
commercial solid phase sandwich ELISA from Biosource
International (Camarillo, CA, USA) was used. TNF-α and
IL-1-β levels were determined from a standard curve for
recombinant TNF-α and IL-1β; and concentrations were
expressed as pg/ml. The ELISA detection limit for TNF-α
and IL-1β were 3 pg/ml.
Determination of Tissue MDA
Tissue MDA assays were performed according to Ohkawa
et al. [16]. Briefly, MDA, the product of lipid peroxidation,
reacts with thiobarbituric acid under acidic conditions at
95°C to form a pink-colored complex with an absorbance
at 532 nm. 1,1,3,3-Tetraethoxypropane was used as the
standard. The results are expressed as nmol/mg protein.
Assessment of Apoptosis
Apoptosis in liver tissues was detected by measuring the
appearance of apoptotic bodies with terminal deoxynu-
cleotidyl transferase-mediated deoxyuridine triphosphate
nick-end labeling (TUNEL) assay using the ApopTag per-
oxidase kit (Invitrogen, Carlsbad, CA), and by pathologi-
cal quantification of apoptotic foci. Approximately 3000
average cells were counted per sample. This specific assay
uses terminal deoxynucleotidyl transferase to attach bioti-
nylated deoxyuridine triphosphate to free 3'-OH DNA
ends. Liver tissue sections (5 µm) were prepared using a
microtome and placed on glass slides. The sections were
deparaffinized in xylene, dehydrated in ethanol, and then
incubated with proteinase K 20 µm/ml in PBS for 20 min-
utes at room temperature. After rinsing the specimen
twice with PBS, the sections were processed following the
instructions of a commercial kit (Dead End Colorimetric
Apoptosis Detection System; Promega, Madison, WI,
U.S.A.). Sections were stained with streptavidin-horserad-
ish peroxidase conjugate, and then counterstained with
hematoxylin. The peroxidase- positive cells were identi-
fied morphometrically by brown staining nuclei. The
numbers of TUNEL-positive cells were counted in 10 ran-
dom microscopic fields (400 ×).
Histopathology
Liver tissues were fixed in 40 mg/ml formaldehyde and
were embedded in paraffin. For histopathological evalua-
tion, 4-µm slides were stained with hematoxylin-eosin,
Masson's trichrom, Periodic acid-Schiff (PAS), and Hall's
stain for bile. Sections were scored by an independent
observer blinded to the experimental protocol. The fol-
lowing lesions were scored according to Modified Histo-
logical Activity Index: [17,18] portal inflammation, focal
necrosis, confluent necrosis, interface hepatitis, and focal
inflammation. The numbers of biliary canals in five portal
sites for each section were also noted.
Statistics
All results were analyzed and are given as the mean ±
standard deviation (SD). Comparisons among multiple
groups were performed using Kruskal- Wallis test. If there
was a significant difference between groups, further paired
comparisons were done by using Mann-Whitney U test.
We have divided conventional significant p value (0.05)
by the total number of groups (n = 4) to find the true p
value for this study. For this reason, the significant value
of p in this study is accepted as below 0.0125 (0.05
divided by 4 = 0.0125)
Results
No deaths were observed during the experiment. All ani-
mals with BDL were obviously jaundiced 3 days after the
operation. The jaundice was confirmed by measuring the
serum total bilirubin concentration on 7th day after BDL
(Table 1). BDL results in severe bile acid-induced liver
injury. BDL is associated with intrahepatic bile acid over-
load and consequent liver injury.
BDL-Induced Hepatopathology and Cholestasis
Serum AST, ALT, GGT, ALP, and TBA levels were signifi-
cantly elevated in all animals in which BDL was per-
formed when compared to sham-operated rats, and the
same parameters were considerably lower in the fenofi-
brate group than other BDL groups (P < 0.01). No signif-
icant difference was observed in the biochemical
parameters between the control and BDL-vehicle groups.
Similarly, although serum direct bilirubin levels were sig-
nificantly elevated in all BDL animals compared withBMC Gastroenterology 2007, 7:44 http://www.biomedcentral.com/1471-230X/7/44
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shams, it was lower after BDL in PPARα activated rats than
other BDL's (P = 0.01).
Proinflammatory Cytokines
Serum TNF-α and IL-1β levels in animals with BDL were
significantly higher than in the sham group (P < 0.01,
Table 1). There were no significant differences in terms of
the cytokines between the BDL and BDL-vehicle groups.
Fenofibrate treatment significantly decreased the serum
TNF-α and IL-1β levels in rats with BDL (P < 0.01, Table
1).
Tissue MDA levels
The levels of MDA, which is the last product of oxidative
injury, were significantly increased after BDL when com-
pared with sham group (P <0.001). Fenofibrate treatment
decreased the MDA levels significantly when compared
with BDL and BDL-vehicle groups (P = 0.01, Table 1).
Histopathologic Examination
Histopathological examination showed that portal
inflammation, interface hepatitis, lobar and confluent
necrosis and bile duct number in rats which underwent
BDL were significantly higher than in sham-operated rats.
Except the bile duct number, all histopathologic parame-
ters in rats administrated fenofibrate markedly decreased
in comparison to control rats and BDL-vehicle. It was
apparent that fenofibrate treatment caused significant
increase in number of bile ducts (P < 0.01, Table 2, Figure
1). The reduction of hepatic necrosis and increase in the
number of bile duct suggest that fenofibrate has regenera-
tive effects.
Apoptosis
Hepatocyte apoptosis in the animals with BDL is signifi-
cantly higher than in sham group (P < 0.001). PPARα acti-
vation significantly decreased apoptosis in rats with BDL
compared to control and BDL-vehicle groups (P < 0.01,
Figure 2).
Discussion
The administration of peroxisome proliferators results in
a marked increase in the number and size of peroxisomes
and size of the liver [5,10,11]. Furthermore; long-term
administration of peroxisome proliferators causes hepato-
cellular carcinoma in rats and mice [5,12,19]. Long-term
Table 1: Change in concentrations of laboratory data (mean ± SD)*
Sham BDL BDL + vehicle BDL + fenofibrate
Bilirubin (mg/dl) 0.68 ± 0.17 9.05 ± 2.24a 8.98 ± 2.78a 6.02 ± 1.56a,b,c
ALT (IU/L) 45.7 ± 9.7 115.7 ± 16.5a 117.4 ± 20.2a 82.7 ± 12.0a,b,c
AST (IU/l) 78.1 ± 9.6 142.8 ± 17.8a 147.7 ± 24.0a 99.4 ± 13.6a,b,c
GGT (IU/l) 7.7 ± 2.7 37.8 ± 8.0a 34.4 ± 13.1a 26.4 ± 6.2a,b,c
ALP (IU/L) 95.9 ± 19.4 408.2 ± 42.4a 416.0 ± 62.6a 381.6 ± 36.9a,b
TBA (µmol/ml) 3.2 ± 1.2 34.3 ± 3.8a 35.7 ± 2.9a 26.7 ± 4.1a,b,c
TNF-α (pg/mL) 6.2 ± 2.57 45.7 ± 4.61a 43.8 ± 5.86a 32.7 ± 5.6a,b,c
IL-1β (pg/mL) 7.3 ± 3.9 130.3 ± 16.6a 128.3 ± 23.9a 83.2. ± 11.3a,b,c
Tissue MDA levels (nmol/
mg protein)
0.5 ± 0.2 4.9 ± 1.2a 4.8 ± 0.9a 2.1 ± 0.4a,b,c
*Comparisons between groups were done by using Kruskal-Wallis test. Paired comparisons are done by using Mann-Whitney U test.
aP < 0.01 versus sham group (Mann-Whitney U after Kruskal-Wallis test)
bP < 0.01 as compared to BDL groups (Mann-Whitney U after Kruskal-Wallis test)
cP < 0.01 as compared to BDL + vehicle groups (Mann-Whitney U after Kruskal-Wallis test)
Table 2: Change in histopathologic scores (mean ± SD)*
Sham BDL BDL + vehicle BDL + fenofibrate
Portal inflammation 0 3.2 ± 0.2a 3.1 ± 0.7a 2.0 ± 0.5a,b,c
Interface hepatitis 0 1.8 ± 0.7a 1.7 ± 0.9a 1.3 ± 0.6a,b,c
Confluent necrosis 0 2.2 ± 0.a 2.1 ± 0.9a 1.1 ± 0.2a,b,c
Lobar necrosis 0 3.0 ± 0.9a 2.9 ± 0.7a 2.1 ± 0.8a,b,c
Bile duct number/5 portal 
field
3.5 ± 1.3 18.9 ± 8.0a 17.5 ± 7.1a 23.2 ± 11.1a,b,c
*Comparisons between groups were done by using Kruskal-Wallis test. Paired comparisons are done by using Mann-Whitney U test.
aP < 0.01 versus sham group (Mann-Whitney U)
bP < 0.01 as compared to BDL group (Mann-Whitney U)
cP < 0.01 as compared to BDL + vehicle group (Mann-Whitney U)BMC Gastroenterology 2007, 7:44 http://www.biomedcentral.com/1471-230X/7/44
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pharmacologic exposure of patients to the hypolipidemic
drugs gemfibrosil, and clofibrate, which are potent rodent
peroxisome proliferators, has not revealed any increased
risk of hepatocellular cancer or others [5,20]. For this rea-
son, we designed this experiment in order to evaluate the
short term effects of fenofibrate treatment for its effects in
decreasing bile production and cholesterol synthesis.
The most important factors for obstructive jaundice are
accumulation of bilirubin, bile acids, and cholesterol in
liver [1]. Bile acid synthesis has been reported to increase
after BDL in animals. Weis and Dietschy [21] showed that
after acute bile duct obstruction, cholesterol synthesis
increased five fold. It has been demonstrated that choles-
terol 7α-hydroxylase activities, catalyzes the first and rate-
limiting step in the major pathway for bile acid biosynthe-
sis from cholesterol homeostasis, increased significantly
after obstructive jaundice [22]. Fibrates inhibit bile acid
synthesis, the major pathway of cholesterol elimination
from the body, by reducing cholesterol 7α-hydoxylase
gene (CYP7A1) and sterol 27-hydoxylase gene
(CYP27A1) expression in rodents [8] and 7α-hydroxyla-
tion rate in humans [9]. Le Jossic-Corcos et al. [7] showed
that fibrates decreased cholesterol efflux, cholesterol con-
version into bile acids and cholesterol ester storage in rat
hepatocytes. In our study, TBA levels in fenofibrate treat-
ment group were significantly lower than control group.
In addition, the fibrates exerted their effects through low-
H & E-stained liver sections of sham operated (A) and BDL (B) rats demonstrate bile-duct dilation, polymorphonuclear cell  infiltrate, bile-duct proliferation (arrow, HE × 20), (C) markedly inflammation, and (D) necrosis (arrow, HE × 200) Figure 1
H & E-stained liver sections of sham operated (A) and BDL (B) rats demonstrate bile-duct dilation, polymorphonuclear cell 
infiltrate, bile-duct proliferation (arrow, HE × 20), (C) markedly inflammation, and (D) necrosis (arrow, HE × 200).BMC Gastroenterology 2007, 7:44 http://www.biomedcentral.com/1471-230X/7/44
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ering serum total bilirubin levels (P  < 0.01). It's well
known that fenofibrates increases the conjugation of
bilirubin and glucoronoid. Fenofibrates might have
decreased the direct bilirubin levels.
In our study, liver enzymes increased after BDL. Although
fenofibrate treatment decreased the levels of these
enzymes, the levels have still remained high when com-
pared with sham group. This might be a result of short
treatment period with fenofibrate.
In histological examination, fenofibrate mediated PPARα
activation significantly decreased lobar and confluent
necrosis. Nevertheless, histological parameters remained
high when compared to sham operated group.
Hepatocellular apoptosis is a common result of accumu-
lation of bile, bile salts and cholesterol [1-3]. Apoptosis
occurs at a constant rate in the liver and this process is
believed to be a means by which old and damaged cells
are eliminated. If not eliminated, cells having DNA dam-
age could potentially become transformed by further
mitogenic stimulation and DNA mutations [22,23]. Nev-
ertheless; inappropriate apoptosis plays an important role
in many diseases. In our study enhanced apoptosis is
observed following BDL.
There are various studies stating that PPARα activation
may increase [14] or decrease apoptosis [10,11]. On the
other hand, according to our knowledge, the effects of
fenofibrate on enhanced apoptosis in the setting of
cholestasis have not been studied. Our study shows that
PPARα activation decreases apoptosis in an experimental
model of cholestasis. PPARα agonists activate nuclear fac-
tor kappa B (NF-κB) in the rat and mouse liver, but not in
the hamster. Rats and mice are sensitive to hepatocellular
hyperplastic effects of PPARα ligands. It has also been
shown that NF-κB has an anti-apoptotic activity in several
cell types, including hepatic cell lines. Cosulich et al.
[24,25] demonstrated that the response of NF-κB to per-
oxisome proliferators by inhibiting apoptosis in hepato-
cytes was provided by use of a dominant negative form of
a subunit IkappaB kinase (IKK)-2 complex that is critical
for activity of the IκB kinase. Ductal proliferation is the
one of the changes occurred in obstructive jaundice [26].
In our study the number of bile ducts significantly
increased in rats with obstructive jaundice. The number of
bile ducts increased with fenofibrate treatment. Activation
of PPAR-α might have affected the tolerability of cholesta-
sis in the increase of the number of bile ducts which may
due to hepatocellular proliferation.
Proinflammatory cytokines, such as TNF-α, and IL-1 beta
enhance liver damage in cholestasis. In our study, fenofi-
brate treatment resulted in a significant decrease in proin-
flammatory cytokine levels. Portal inflammation and
interface hepatitis significantly increased 7 day following
the BDL. At the same time serum levels of TNF-α and IL-1
β in rats with obstructive jaundice showed significant
increases. Fenofibrate treatment decreased histopatholog-
ical findings of inflammation, and decreased the cytokine
levels significantly. PPARα has been demonstrated to act
as a negative regulator of genes involved in the inflamma-
tory response by antagonizing the activity of transcription
factors, such as activated protein-1 expression, partly by
direct interaction with proteins such as p65 and c-Jun
[27]. The induction of PPARα may have resulted in
decreased inflammation through altered acute phase reac-
tants.
Increased activation of Kupffer cells after obstructive jaun-
dice affects not only inflammation but also the oxidative
injury. MDA which is the end product of oxidative injury
and lipid peroxidation increased in obstructive jaundice.
In our study MDA levels significantly increased after BDL,
also. This increase significantly decreased after fenofibrate
treatment. Oxidative injury has decreased due to the
increased level of antioxidant enzymes [28] as a result of
PPAR-α activation.
Conclusion
Short-term induction of nuclear receptor PPARα by fenof-
ibrate decreases hepatocellular necrosis, oxidative damage
and inflammation and consequently hepatic damage. Fur-
thermore, although these results suggest a beneficial effect
of fenofibrate, the administration of these drugs in the
treatment of cholestatic patients still remains to be a mat-
ter of debate [29-31] and needs further experimental and
clinical studies. Especially; the alteration in the bile pro-
duction and induction of bile duct proliferation are
TUNEL-positive cells per field Figure 2
TUNEL-positive cells per field. Apoptosis in rats with BDL 
was significantly higher than sham-operated rats (P < 0.01, 
Kruskal-Wallis test). BDL = Bile duct ligation, BDL + F = BDL 
+ fenofibrate, BDL + V = BDL + vehicle.BMC Gastroenterology 2007, 7:44 http://www.biomedcentral.com/1471-230X/7/44
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important points that the researchers should pay atten-
tion for the use of these drugs in the treatment of obstruc-
tive jaundice.
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